Graphical abstract

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors







Tumor biopsies from PR patient outlined in red (B). Pre-treatment above, On-treatment below.

Present during treatment are higher numbers of CD8 and CD4 T cells.

CD3 CD4 CD8 Ki67 Nucleus

In Brief

A. Pixatimod activates DC via TLR9 to engage T cells and NK cells.
Cold tumors, such as MSS CRC, contain limited immune cells and are resistant to checkpoint inhibitor drugs such as nivolumab.

B. This study evaluated pixatimod in combination with nivolumab and detected signs of clinical benefit for MSS CRC patients.

C. It also found evidence of increased T cell tumor infiltration and biomarkers that correlate with clinical benefit.

Authors
Charlotte Lemech, Keith Dredge, Darryn Bampton, Edward Hammond, Andrew Clouston, Nigel J. Waterhouse, Amanda C. Stanley, Lucie Leveque-El Mouttie, Grace M. Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P. Brown, David Goldstein